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Résumé 
Le diagnostic de certaines maladies infectieuses peut être parfois difficiles et de nouvelles 
procédures diagnostiques sont évaluées régulièrement pour répondre à cette problématique. 
La tomographie par émission de positron au 
18
Fluorodeoxyglucose couplée au scanner 
(
18
FDG-PET/CT) a été évaluée dans de nombreuses maladies infectieuses et ses résultats sont 
contrastés. L’analyse de la littérature permet tout de même de tirer quelques conclusions. 
Premièrement, le 
18
FDG-PET/CT n’est en l’état actuel des choses, pas un examen de première 
intention dans le contexte des maladies infectieuses. Deuxièmement, son utilité semble 
acquise dans l’évaluation des patients présentant une fièvre d’origine indéterminée. Sa valeur 
prédictive négative est notamment de 100% : les patients présentant ce symptôme avec un 
premier bilan et un 
18
FDG-PET/CT négatifs voient quasi systématiquement leur fièvre 
spontanément disparaître sans qu’aucune pathologie n’apparaisse dans le suivi. 
Troisièmement, le 
18
FDG-PET/CT semble également avoir un intérêt dans le diagnostic des 
infections de prothèses vasculaires ou d’ostéomyélite. Quatrièmement, ses performances chez 
les patients présentant une endocardite infectieuse notamment pour le diagnostic de 
localisations infectieuses secondaires ou chez les patients avec suspicion d’infection de pace 
maker ou de défibrillateur implantable sont prometteuses mais encore préliminaires. Enfin, les 
résultats des études s’étant intéressés au  18FDG-PET/CT dans d’autres maladies infectieuses 
ne permettent actuellement pas de le recommander pour ces autres situations. 
Mots clés :
18
FDG-PET/CT, fièvre d’origine indéterminée, endocardite infectieuse, infection 
de prothèse vasculaire, ostéomyélite 
 
 
 
Abstract  
The diagnosis of someinfectious diseases is sometimes difficult to make and new diagnostic 
tools have been regularly assessed to that end. 
18
Fluoro-deoxyglucose (
18
FDG) positron-
emission tomography (PET) coupled with computed tomography (CT) is one of these new 
procedures. It has been evaluated for numerous infectious diseases with uneven results. A 
literature reviewallowed drawing some conclusions. First, 
18
FDG-PET/CTis not currently a 
first-line procedure for infectious diseases. Second, it has proveduseful for the evaluation of 
patients presenting with fever of unknown origin (FUO).Its negative predictive value is 
100%: the symptoms of patients experiencing FUO with negative first-line investigations and 
a negative 
18
FDG-PET/CT will almost always spontaneously disappear. Third, 
18
FDG-
PET/CTalso seems to be contributive for the diagnosis of vascular prosthesis infections or 
osteomyelitis. Fourth, it has promising results for patients presenting with infective 
endocarditis, especially forsecondary infectious foci, or for patients presenting with suspected 
infection of pacemakers or implanted defibrillator; but results are still preliminary and must 
be confirmed. Finally
18
FDG-PET/CT cannot be recommended yet for other infectious 
diseases due to lack of published data. 
Keywords:
18
FDG-PET/CT, fever of unknown origin, infective endocarditis, vascular 
prosthesis infection, osteomyelitis 
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1. Introduction: 
Early diagnosis is crucial for the optimal management of patients presenting with infectious 
diseases. Most of the time, this diagnosis is quite easily to makewith usual microbiological or 
imaging investigations. Sometimes, it can be challenging, and new investigational techniques 
are needed. Metabolic and functional imaging techniques maybe usefulin these difficult 
clinical presentations, andscintigraphic or nuclear medicine procedures have been developed 
recently to deal with these. 
18
Fluoro-deoxyglucose (
18
FDG) positron-emission tomography 
(PET) is one of the new tools[1]. PET delivers high-resolution images using biologically 
active compounds labeled with positron emitters. 
18
FDG, a radiolabeled glycogen analogue, is 
accumulated in hypermetabolic cells, such as malignant cells that present with increased 
intracellular glucose metabolism[2], and is frequently used in oncology[3,4]. 
18
FDG is 
injected intravenously, and thenthe PET camera can identify hypermetabolic foci by detecting 
the positron emission of this radiolabeled tracer.A semi-quantitative analysis is performed by 
determining the Standardized Uptake Value (SUV), which is related to the concentration of 
18
FDG in the hypermetabolic foci detected. 
18
FDG-PET/CT combines many advantages when associated with computed tomography 
(CT): optimal spatial resolution, accurate anatomical localization of abnormalities, rapid 
diagnostic results, whole-body analysis, and lack of metallic hardware artifacts[1,5,6]. 
However, kidneys, bladder, brain, and meninges have a high metabolism in normal condition 
and 
18
FDG-PET/CT results can therefore be difficult to interpret for those tissues or 
organs[1]. 
Inflammatory cells involved in host response to infectious diseases also present with 
enhanced metabolism[1]. The contribution of
18
FDG-PET/CT roles for the diagnosis of 
infectious diseases has therefore been considered for many years[7]. An increasing number of 
articlesfocusing on the relevance of
18
FDG-PET/CT in various infectious conditionshave been 
published [1,6]. However, the exact contributionof 
18
FDG-PET/CT forthe diagnosis of 
infectious diseases has not been determined yet. We had foraim to focus on the useof this 
modern technique in the management of patients with suspected or confirmed infectious 
diseases: 
18
FDG-PET/CT seems to be clearly indicated in a few indications but dataon the 
relevance of this imaging technique is still lacking for most infectious diseases. 
 
2. Investigating fever of unknown origin 
Fever of unknown origin (FUO) is defined as a fever ≥ 38.3°C, lasting for at least 3 weeks, 
without any diagnosis after 3 days of investigations forinpatient or 3 outpatient consultations 
[8,9]. No diagnosis can be made in up to 50% of cases despite a modern management [10]. 
FUO is probably the case in which 
18
FDG-PET/CT has been the most frequentlyevaluated[1]. 
Blockmans et al. investigated the clinical contributionof 
18
FDG-PET/CT for patients with 
FUO and compared its results to those of Gallium scintigraphy in the late nineties [11]. Fifty-
eightpatients were included and underwent 
18
FDG-PET/CT. A final diagnosis was made for 
38 (42%). Forty-six
18
FDG-PET/CT results were abnormal and 42% of these abnormal scans 
were considered helpful for the diagnosis, compared to only 25% for Gallium scintigraphy. 
The authors concluded that 
18
FDG-PET/CT should replace Gallium scintigraphy as nuclear 
medicine investigation for patients presenting with FUO. Many other studies have been made 
since [12-20]. All of them had for objective to assess 
18
FDG-PET/CT as acomplementary 
procedure to routine investigations performed for patients presenting with FUO, including 
CT-scan or magnetic resonance imaging (MRI).Most of these studies yielded good results. 
Sensitivities and specificities wereoften lacking because a final diagnosis wasnot always 
made, but positive predictive values (PPV) and negative predictive values (NPV) ranged 
respectively from 30% to 97% and from 50% to 100% (table 1). Another value has been often 
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calculated in theses studies: the probability for 
18
FDG-PET/CT to contribute to the diagnosis. 
In some situations, diagnosis is possible only if 
18
FDG-PET/CT is performed. On the other 
hand, it may be difficultto conclude to the absence of any disease in a patient with FUO and a 
normal 
18
FDG-PET/CT, since no other investigational procedure is available, and in this 
specific situation,
18
FDG-PET/CT did not contribute to diagnosis (table 1).This probability for 
18
FDG-PET/CT to contribute to the diagnosis ranged from 16% to 69%, except in 1 study 
described later [18]. These results could seemunsatisfactory but they wereactually very good: 
they concerned patients with no diagnosis after an exhaustive routineinvestigation, including 
modern imaging techniques (CT-scan, MRI), for FUO. Obtaining a diagnosis thanks to a new 
investigational toolwastherefore very difficult and those results were excellent. Keidar et al. 
[18]illustrated this point with48 consecutive patients presenting with FUO who were 
prospectively enrolled. 
18
FDG-PET/CT was negative for 21 patients and positive for 27 others 
(56%). A diagnosis was obtained for 22 patients with positive 
18
FDG-PET/CT. The main 
interest of this study wasthe very long patient follow-up period: 12 to 36 months. Thus, the 
authors were able to confirm the PPV and the NPV of 
18
FDG-PET/CT in their study. 
Sevenpatients with negative PET-scan were diagnosed as having drug-induced fever (1 
patient), non-focal infection (1 patient with Q-fever, 1 with typhoid fever,and 1 with 
cytomegalovirus viremia), or urinary tract infection (3 patients) for which 
18
FDG-PET/CT is 
known to be weaklyefficient. All the remaining patients with negative PET-scan had 
aspontaneous resolution of fever with no otherevidence of a localized inflammatory, 
infectious, or malignant disease during follow-up. Four of the 5undiagnosed patients with 
positive 
18
FDG-PET/CTalso had spontaneous resolution of fever. A Still disease was 
diagnosed for the otherone. The authors concluded that the PPV and NPV of 
18
FDG-PET/CT 
in their studywere respectively 81 and 100%, highlighting the contribution of a negative 
18
FDG-PET/CT forpatients presenting with FUO. 
18
FDG-PET/CT thus seems clearlycontributive forthemanagement of patients presenting with 
FUO (figure 1).A structured diagnostic protocol relying onthis imaging procedure is proposed 
in figure 2.A national prospective study coordinated by the Limoges nuclear medicine 
department,focusing on the contribution of this procedure for FUO, has just ended and results 
of this study should help clinicians in this clinical presentation. 
 
3. Musculoskeletal infections 
a. Osteomyelitis and spondylodiscitis 
The diagnosis of subacute or chronic osteomyelitis can be difficult, especially in case of 
preexisting alterations of osseous structures due to previous surgery or trauma. The results of 
conventional imaging are often non-specific[1]. The results of conventional nuclear medicine 
procedures can also be weakly sensitive, specific, or both, and have poor spatial resolution[1]. 
18
FDG-PET/CTwas very effective in this clinical presentation. de Winter et al.conducted 
prospective study on the contribution of 
18
FDG-PET/CTfor the diagnosis of chronic skeletal 
infections in 60 patientshaving undergone recent surgery. They reported a sensitivity, 
specificity, and overall accuracy of 100%, 86%, and 93% respectively[21]. Hartmann et al. 
retrospectively assessed the diagnostic contribution of 
18
FDG-PET/CTfor 33 patients 
presenting with suspected post-traumatic chronic osteomyelitis[22]. The sensitivity, 
specificity, and accuracy were 94%, 87%, and 91% respectively. The NPV was 97% in this 
study.  
The authors of a meta-analysis comparing 
18
FDG-PET/CT’s performance to that of other 
imaging tools published in 2005, demonstrated a pooled-sensitivity of 96%, a pooled-
specificity of 91%, and the superiority of 
18
FDG-PET/CT to other techniques for the 
diagnosis of chronic osteomyelitis (table 2)[23].  
PET/CT was also evaluated for spondylodiscitis. The clinical contribution of this technique 
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was less clearly determined, especially since MRI is highlysensitive and accurate in detecting 
vertebral osteomyelitis[1]. However, 
18
FDG-PET/CTcould be helpful to differentiate between 
active degenerative lesions and infectious end-plate abnormalities, and in cases where MRI is 
less efficient, such as suspicion of vertebral osteosynthesis infection [24,25]. It could also be 
useful for the evaluation of response to therapy in patientspresenting with 
spondylodiscitis[26]. Again, the clinical relevance of these results was not clearly defined 
since clinical evaluation was most of the time sufficient to evaluate the effectiveness of 
spondylodiscitis treatment. 
 
b. Diabetic foot 
Peripheral neuropathy is common in patients presenting with diabetes mellitus and 5 to 10% 
of diabetic patients have foot ulcers that evolve to osteomyelitis[27]. It is sometimes difficult 
to discriminate between infectious process and Charcot’s osteoarthropathy, the end-stage 
diabetic peripheral neuropathy. Hyperglycemia can affect 
18
FDG-PET/CT results and this 
procedure may be difficult to apply for diabetic patients. Nevertheless, the quality of PET/CT 
images to assess infection in diabetic patients is optimal when glycaemia levels are inferior to 
250 mg/dL[28]; and this technique has been assessed for the diagnosis of infection in patients 
presenting with diabetic foot. Keidar et al.[29]evaluated the contribution of 
18
FDG-
PET/CTfor the diagnosis of suspected osteomyelitis in 14 patients presenting with diabetic 
foot. This technique allowed identifying osteomyelitis in 8 out of 8 sites, and soft tissue 
infection in 5 out of 5 sites, while CT alone allowed identifying osteomyelitis in 7 out of 8 
sites and soft tissue infection in 4 out of 5 sites. The authors concludedthat 
18
FDG-PET/CT 
was an effective techniquefor the diagnosis of osteomyelitis in patients presenting with 
diabetic foot, and to discriminate between soft tissue and bone infection. 
18
FDG-PET/CT can 
also yield hypermetabolismin Charcot’s osteoarthropathy without any osteomyelitis[30] and 
the specificity of 
18
FDG-PET/CT may betherefore questioned. Basu et al. investigated this 
point in a prospective study on 63 patients in 4 groups: 20 non-diabetic patients with normal 
lower extremities, 21 patients presenting with uncomplicated diabetic foot, 17 patients 
presenting with Charcot’s arthropathy, and 5 patients presenting with proven osteomyelitis 
secondary to a complicated diabetic foot[31]. The mean standardized uptake values (SUV) in 
healthy individuals and patients presenting with uncomplicated diabetic foot were 0.42 +/- 
0.12 and 0.5 +/- 0.16 respectively (P>0.05). The mean SUV for Charcot’s arthropathy and in 
osteomyelitis were 1.3 +/- 0.4 and 4.38 +/- 1.39. Differences were statistically significant 
(P<0.01) between these 2 groups and between Charcot’s arthropathy group and healthy 
controls orpatients presenting with uncomplicated diabetic foot. Theseauthors concluded that 
18
FDG-PET/CT was a relevant imaging technique for the diagnosis of diabetic foot. However, 
the number of patients includedin all those studies was rather small and further investigations 
are needed. For instance, even if 
18
FDG-PET/CT appears to be more effective than Gallium 
scintigraphy for this indication, no comparison between 
18
FDG-PET/CT and radiolabeled 
leukocytes scintigraphy has been made so far and such a comparative study would be greatly 
contributive to determine the role of 
18
FDG-PET/CT for the diagnosis of patients witha 
suspected diabetic foot infection. 
 
c. Infected prosthesis 
18
FDG-PET/CT seems to have a great potential for the investigation of patients with 
suspected orthopedic prosthetic infection, since the procedure is weakly affected by artifacts 
from metallic implants. It may be contributive to discriminate between aseptic loosening and 
periprosthetic infection. The authors of a preliminary prospective study including 62 patients 
evaluated the accuracy of 
18
FDG-PET for the investigation of painful lower limb 
prostheses[32]. A final diagnosis was made by surgical exploration or clinical follow-up for 1 
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year. The sensitivity, specificity, and accuracy of PET were 90.9%, 72%, and 77.8% 
respectively to detect infection in knee prosthesis. The results for the detection ofinfection in 
hip prosthesis were better with a sensitivity, specificity, and accuracy of 90%, 89.3%, and 
89.5% respectively. The reason why 
18
FDG-PET was more accurate for the diagnosis of 
infection in hip than in knee prostheses was unclear. Those results were later confirmed. Pill 
et al. compared 
18
FDG-PET to 
111
Indium-white blood cell imaging for the diagnosis of hip 
prosthetic infections [33]. Eighty-nine patients presenting with painful hip prostheses were 
prospectively included and underwent 
18
FDG-PET and 
111
Indium-white blood scintigraphy,or 
18
FDG-PET alone. The diagnosis of total hip arthroplasty infection was secondarily 
confirmed or invalidated by surgery and microbiological samples harvested during surgery. 
18
FDG-PET allowed diagnosing 20 out of the 21 infected prostheses (sensitivity, 95.2%) and 
ruled out infection in 66 out of the 71 aseptic hip prostheses (specificity, 93%). The PPV and 
NPV were 80% and 98.5% respectivelyin this study. 
111
Indium-white blood scintigraphy was 
less efficient with a sensitivity, specificity, PPV, and NPV of 50%, 95.1%, 41.7%, and 88.6% 
respectively. However, the same group of investigators also demonstrated a lack of specificity 
for the detection of hip prosthetic infections [34]. They prospectively enrolled 9 patients 
having undergone total hip arthroplasty, followed-up by 
18
FDG-PET at 3, 6, and 12 months 
after surgery. Their aim was to assess the patterns and time course of FDG accumulation after 
total hip replacement. They also retrospectively analyzed the clinical data of 18 other patients 
who had undergonearthroplasty and
18
FDG-PET/CT for oncologic indications. All the 
included patients were totally asymptomatic. The results were demonstrative: in 81% of the 
cases, increased FDG uptake was noted around the femoral head or neck part of the 
prosthesis. The averagedelay between surgery and 
18
FDG-PET procedure was 71.3 months 
for these patients with a maximum of 288 months. There was no increased FDG uptakein 
only 4 patients, but the averagedelay between surgery and 
18
FDG-PET procedure was much 
longer in these patients: 114.8 months. Therefore, surgery can induce an inflammatory 
reaction and thus a prolonged FDG increased uptake, which may complicate the results of 
18
FDG-PET procedure in case of infection suspected to be related to the orthopedic 
prosthesis. Moreover, Chacko et al.[35] demonstrated that the level of FDG uptake could not 
be used to discriminate between aseptic loosening and prosthesis infection. Thirty-two 
patients presenting with painful hip prosthesis underwent 
18
FDG-PET before prosthesis 
replacement. Twelve of them presented withprosthesis infection proven by microbiological 
samples harvested during surgery. Eleven of these patients displayed moderately increased 
FDG uptake along the interface between the bone and prosthesis, with SUVs inferior to 2 in 
some cases. All the 
18
FDG-PET performed in the 20 patients presenting withaseptic loosening 
proved the increased FDG uptake with much higher SUVs than the one found in septic 
patients, ranging from 1.5 to 7. The authors concluded that the amount of FDG uptake was 
not a marker of prosthetic infection. Nevertheless, the same authors[35] and 
others[1]suggested that there was a specific FDG uptake pattern for hip prosthetic infection: 
FDG uptake between the bone and prosthesis, at the mid-shaft level of the prosthesis, but not 
at other levels, could be specific of infection. 
Thus,
18
FDG-PET/CT may be contributive for the evaluation of suspected prosthesis related 
infection but major concerns remain related to its specificity (prolonged increased FDG 
uptake after surgery) and other studies are needed to determine its clinical usefulness in this 
clinical presentation. 
 
4. Bacteremia and cardiovascular diseases 
a. Bacteremia 
Bacteremia, and especially Gram-positive bacteremia, can lead to metastatic infectious foci 
and early diagnosis of these secondary infectious sites is crucial since they require prolonged 
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antibiotic treatment and, sometimes, drainage. Some authors assessed 
18
FDG-PET/CTfor the 
detection of metastatic infectious foci,in Gram-positive bacteremia, to determine whether this 
could positively influence the clinical outcome[36]. One hundred-fifteen patients presenting 
with Gram-positive bacteremia (73 due toStaphylococcus aureus, 30 toStreptococcus sp., and 
12 toEnterococcus sp.) were prospectively recruited. 
18
FDG-PET/CT was performed within 2 
weeks after the first positive blood culture, in addition to other usual investigations. These 
patients were compared to a matched historical control group of 230 patients for whom no 
18
FDG-PET/CT was performed. More metastatic infectious foci were diagnosed in the study 
group than in the control group (67.8% vs. 35.7%, P<0.01). Metastatic foci were 
asymptomatic in 35 patients (30%) and would have not been diagnosed without 
18
FDG-
PET/CT. More interestingly, the mortality rate at 6 months was lower in the study group than 
in the control group:  19.1% vs. 32.2% (P=0.014). These results were later confirmed by the 
same group of investigators in a study including only staphylococcal and streptococcal 
bacteremia[37], and in a cost-effectiveness analysis[38]. However, there were some 
limitations in those studies. First, they were not randomized comparative studies and 
historical comparisons provide less robust conclusions than randomized trials. Second, there 
were important discrepancies between the 2 groups: i) echocardiography was performed more 
often in the study than in the control group (83% vs. 29%, P<0.001), and therefore the rate of 
infective endocarditis among patients of the control group was probably underestimated (8% 
vs. 18% in the study group, P<0.01), with an impact on the treatment and the outcome; ii) 
treatment was more frequently delayed in the control group (45% vs. 27%, P=0.01); iii)the 
median treatment duration was shorter in the control group than in the study group. Patients 
without documented secondary infectious foci were treated 14 days even in case of S. aureus 
bacteremia. More patients received only 14 days of antibiotics in the control group than in the 
study group since more metastatic infectious sites were identified in the study group. This 
duration of treatment seemedrather short for S. aureus bacteremia since the absence of 
metastatic sites of infection was a necessary but not a sufficientcondition to treat such 
infections only 14 days [39,40]. To conclude, 
18
FDG-PET/CT may be contributivefor the 
investigationof patients presenting with Gram-positive bacteremia, but data is still lacking and 
this expensive procedure cannot be recommended currently for this clinical presentation. 
 
b. Infective endocarditis 
The modified Duke criteria are considered to be the gold standard for the diagnosis of 
infective endocarditis (IE)[41]. However, this diagnosis can be challenging, especially in case 
of prosthetic valve endocarditis (PVE), for which echocardiography can be inconclusive in 
almost 30% of cases[42]. Thus, 
18
FDG-PET/CT could be a promising diagnostic procedure in 
these cases. The authors of 2 important studies assessed the contribution of 
18
FDG-PET/CT 
for IE. The authors of the first study prospectively included 72 patients presenting with Gram-
positive bacteremia who underwent echocardiography and 
18
FDG-PET/CT[43]. IE was 
defined according to the modified Duke criteria. Patients werefollowed-up for 6 months after 
the first positive blood culture.  Eighteenpatients (25%) were diagnosed with proven IE, 10 
with S. aureus endocarditis and 8 with streptococcal endocarditis. Twoof these were 
diagnosed with PVE. Enhanced valve FDG uptake on 
18
FDG-PET/CTwas demonstrated in 
only 7 patients presenting with IE. High FDG uptake in heart valves was demonstrated in 4 
patients without IE. Two of these 4 patients had undergone heart valve replacement 27 days 
and 7 years earlier. Overall, sensitivity and specificity of 
18
FDG-PET/CT for the diagnosis of 
IE in this study were 39% and 93% respectively. The PPV was 64%, the NPV was 82%, and 
the authors concluded that 
18
FDG-PET/CT was not contributive enough for the diagnosis of 
IE. 
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The authors of the second study evaluated the diagnostic value of 
18
FDG-PET/CT for 
PVE[44]. They prospectively studied 72 consecutive patients presenting with suspected PVE. 
All of the patients underwent routine investigations for suspected PVE including exhaustive 
microbiological workup, transthoracic and transoesophageal echocardiography. 
18
FDG-
PET/CT was also performed at admission. An expert team made the final diagnosis 
determined during a 3-month follow-up after admission, according to the modified Duke 
criteria. The results were: sensitivity 73%, specificity 80%, PPV 85%, NPV 67%, and global 
accuracy 76%. It should be noted that when abnormal FDG uptake around the prosthetic 
valve was added as a new major criterion, the sensitivity of thesenew modified Duke criteria 
at admission increased from 70% to 97% (P=0.008), without any decrease of specificity. This 
result was related to a significant reduction in the rate of "possible IE" from 56% to 32% 
(P<0.0001). However, despite those very promising results, it seemed difficult to 
systematically encourage the performing
18
FDG-PET/CT for the diagnosis of IE. The current 
modified Duke criteria are sufficient for the diagnosis of IE most of the time. We believe 
that
18
FDG-PET/CT should be used only in the very difficult cases of patients withsuspected 
PVE for whom the modified Duke criteria cannotallow making a final diagnosis. It could also 
be performed for patients presenting with IE, remaining febrile despite an appropriate 
treatment. It could allow detecting secondary infectious foci requiring specific treatment. This 
presentation is very similar to FUO for which 
18
FDG-PET/CT prove highly valuable. A 
national French multicenter study will begin in 2014 to evaluate the accuracy of this 
procedure for the diagnosis of secondary infectious foci during IE. 
 
c. Infection of cardiovascular implantable electronic devices  
Infection of cardiovascular implantable electronic devices (CIED) is a serious complication 
and can lead to complete removal. The diagnosis of pocket infection is most often easy to 
make, while the diagnosis of lead infection is often more challenging. The authors of a pilot 
study evaluated the contribution of 
18
FDG-PET/CT for patients suspected of having sepsis 
after CIED implantation[45]. Twenty-onepatients presenting with suspected device infection 
were prospectively included and compared with 14 controls. The final diagnosis was made 
according to either bacteriological data after device culture or, when no device was extracted, 
on a 6-month follow-up according to the modified Duke criteria and not according to 
18
FDG-
PET/CT results. These results were compared to the final diagnosis obtained for each patient 
to determinate the accuracy of this technique. The sensitivity, specificity, PPV, and NPV were 
respectively 100%, 100%, 100%, and 100% for pocket infections,but only 60%, 100%, 100%, 
and 73% for lead infections which are the most difficult to diagnose. It should be noted that 4 
patients with false negative lead infection received antibiotics before 
18
FDG-PET/CT’s was 
performed for longer than the 6 true positives (20 days vs. 3.2 days, P<0.01). The authors 
concluded that negative 
18
FDG-PET/CT should be interpreted with caution for the diagnosis 
of CIED infection, especially in patients having previously received antibiotics. 
The authors of a second study investigated the impact of 
18
FDG-PET/CT on the management 
of patients suspected of having a CIED infection[46]. Fourty-two patients suspected of having 
an infection were compared to 12 patients without infection in whoma CIED had been 
implanted 4 to 8 weeks earlier, and to 12 other patientsin whom a CIED had been implanted 
for more than 6 months, without infection. All these patients underwent 
18
FDG-PET/CT. A 
final diagnosis of CIED infection was made for 35 of the 42 patients suspected of having an 
infection. The sensitivity and specificity of 
18
FDG-PET/CT were respectively 89% and 86%. 
The SUVs were much higher in infected patients than in patients who had been implanted 
recently. There was no enhanced FDG uptake in any of the patients implanted for more than 6 
months. Sixof the patients presenting with CIED infection, had superficial FDG uptake 
limited to subcutaneous tissues, without any contact with generator or leads, and were 
 9 
considered to have only superficial infections. They were treated with antibiotics alone, 
without any material removal. The 6 patients were free of infection after a 9-month follow-up. 
The authors concluded that 
18
FDG-PET/CT could be useful in the management of patients 
suspected of having a CIED infection,to assess the extension of the infectious process and to 
help restrict lead removal to the appropriate patients.  
18
FDG-PET/CT may be help to diagnose CIED infection and some authors have reported 
promising results. Nevertheless, the sample sizes of these studies were small and more data 
areneeded to determine the true indications of 
18
FDG-PET/CT in this type of infection. 
 
d. Vascular prosthesis infection 
18
FDG-PET/CT seems to bea very promising diagnostic tool for vascular prosthesis infection. 
CT-scan remains the first-line diagnostic procedure but results provided are not always 
conclusive and 
18
FDG-PET/CT might be very helpful in this case. Keidar et al.studied the 
contribution of 
18
FDG-PET/CT for the diagnosis of suspected vascular grafts infections[47]. 
Thirty-ninepatients were included in this non-comparative prospective study and underwent 
18
FDG-PET/CT. The final diagnosis was based on histopathological and/or microbiological 
findings obtained during surgery or onclinical and imaging follow-up. Vascular graft 
infection was confirmed in 14 patients. The sensitivity of 
18
FDG-PET/CT was 93% and its 
specificity 91%. The PPV and NPV were respectively 88% and 96%. Another study assessed 
the effectiveness of 
18
FDG-PET/CT compared to that of CT in 33 consecutive patients 
presenting with suspected aortic prosthetic graft infection[48]. Although both imaging 
procedures were effective, 
18
FDG-PET/CT seemed to besuperior to CT in some 
circumstances. Twopatterns of FDG uptake were documented: i) linear, along the graft wall, 
due to a physiological inflammatory response to a foreign body, which may persist for years, 
and ii) focal, highly suggestive of prosthesis infection (figure 3). The specificity and PPV of 
18
FDG-PET/CT for the diagnosis of aortic prosthesis graft infection was superior to 95% 
when focal uptake was the only positive criterion. Those results were later confirmed, in 
astudy including the highest number of patients performed to date:Spacek et al.prospectively 
investigatedthe contribution of 
18
FDG-PET/CT in 76 consecutive patients for 96 vascular 
prosthesis grafts in which infection was suspected[49]. They found that the sensitivity, 
specificity, PPV, NPV, and overall accuracy of 
18
FDG-PET/CT were respectively 98.2%, 
75.5%, 84.4%, 96.9%, and 88.5% when all the PET/CT with enhanced FDG uptake were 
considered as the positive criteria. The results were much betterwhen only PET/CT with focal 
homogenous FDG uptake enhancement were considered as demonstrative ofinfection, with a 
sensitivity of 97.7%, a specificity of 91.2%, a Pouf 93.5%, a Novo 96.9%, and a 
globalaccuracy of 94.9%. 
CT-scan is most of the time conclusive for the diagnosis of vascular prosthesis infection, thus 
18
FDG-PET/CT cannot be recommended as a first line investigation tool in this case. 
However, we think that 
18
FDG-PET/CT is the procedure of choice for the diagnosis of this 
very severe infection when CT-scan is inconclusive, although data comparing 
18
FDG-PET/CT 
and radiolabeled leukocyte scintigraphy is still lacking for this type of infection. 
 
5. Miscellaneous infections 
18
FDG-PET/CT was evaluated in many other infectious diseases: in tuberculosis to monitor 
early therapeutic response[50,51], in intensive care units to rule out important infections in 
mechanically ventilated patients[52], in HIV infection to determine lymphoid tissue 
activation[53] or to discriminate between cerebral toxoplasmosis and cerebral lymphoma[54], 
etc. However, the authors of these studies provided very limited and preliminary data and 
18
FDG-PET/CT should be used in those indications only in clinical trial settings and not 
routinely. 
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6. Conclusion 
18
FDG-PET/CT is a very promising imaging procedure for the diagnosis of infectious 
diseases. It is not used for first line investigation but can be very helpful in infectious diseases 
when the diagnosis is difficult to make such as for FUO and vascular prosthesis infection. It 
can also be contributive when vertebral osteosynthesis device infection is suspected, since 
MRI results can be difficult to interpret, and in diabetic foot with suspicion of 
osteomyelitis.The results are promisingin case of IE to detect secondary infectious foci, or for 
prosthetic valve endocarditis difficult to diagnose and future studies will promptly start and 
supply more definitive answers. Other indications will probably be considered in the near 
future but studies evaluating its relevance are still needed to further determine the real 
contribution of 
18
FDG-PET/CT for the diagnosis of infectious diseases.  
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Tableau 1: résultats des étudesdédiées à l'évaluation du
18
FDG-PET/CT chez les patients avec 
une fièvre d’origine indéterminée 
Table 1: results of studies dealing with the evaluation of 
18
FDG-PET/CT for patients 
presenting with fever of unknown origin 
 
First author Year Method 
Number of 
patients 
Useful for 
thediagnosis 
Negative 
predictive 
value 
Positive 
predictive 
value 
Meller[12] 2000 Prospective 20 55% 75% 92% 
Stumpe[13] 2000 Retrospective 39 ND 100% 97% 
Lorenzen[14] 2001 Retrospective 16 69% 100% 92% 
Bleeker-
Rovers[15] 
2004 Retrospective 35 37% 95% 87% 
Kjaer[16] 2004 Prospective 19 16% 69% 30% 
Bleeker-
Rovers[17] 
2007 Prospective 70 33% 92% 70% 
Keidar[18] 2008 Prospective 48 89% 100% 81% 
Sheng[19] 2011 Prospective 48 66% 50% 80% 
Seshadri[20] 2012 Prospective 23 61% 78% 86% 
ND: No Data 
 
Tableau 2: résultats comparésde
18
FDG-PET/CT, scintigraphie osseuse, scintigraphieaux 
leucocytes, scintigraphie auGallium, etIRMpour le diagnosticd'ostéomyélitechronique (selon 
Termaat et al.[23]) 
Table 2: comparative results of 
18
FDG-PET/CT, bone scintigraphy, leukocyte scintigraphy, 
Gallium scintigraphy, and magnetic resonance imaging for the diagnosis of chronic 
osteomyelitis (according to Termaat et al.[23]) 
 
 
Sensitivity 
(Confidence Interval 95%) 
Specificity 
(Confidence Interval 95%) 
18
FDG-PET/CT 
 
96% (88%-99%) 91% (81%-95%) 
Bone scintigraphy 82% (70%-89%) 25% (16%-36%) 
Leukocyte scintigraphy 61% (43%-76%) 77% (63%-87%) 
Combined bone and leukocyte scintigraphy 78% (72%-83%) 84% (75%-90%) 
Gallium scintigraphy 56% (26%-82%) 76% (49%-91%) 
Magnetic resonance imaging 84% (69%-92%) 60% (38%-78%) 
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Figure 1: 
18
FDG-PET/CT une fièvre d’origine indéterminée 
Figure 1: 
18
FDG-PET/CT for fever of unknown origin 
 
A 72-year old woman was hospitalized for recurrent liver abscesses. A first CT-scan was 
considered as non-conclusive (data not shown). 
18
FDG-PET/CT demonstrated hyper 
metabolism in the liver (abscess already known, arrow A), but also in the pelvis (arrow B). A 
centered image demonstrated the presence of a rabbit bone inside the sigmoid (arrow C) with 
surrounding digestive ulcerations contributing to these recurrent liver abscesses. After surgery 
and rabbit bone removal, the patient no longer presented with any liver abscess. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
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Figure 2: proposition de protocole diagnostic structurépour l'utilisation de
18
FDG-PET/CT 
chez les patients avec une fièvre d’origine indéterminée 
Figure 2: proposed structured diagnostic protocol for 
18
FDG-PET/CT inpatients presenting 
with fever of unknown origin 
 
Fever of unknown origin 
 
 
History and physical examination 
 
 
Exclude drug induced fever 
 
 
First level investigations* 
 
 
HypothesisNo hypothesis 
 
 
Guided diagnostic test (biopsy, etc.)                                            Second level investigations** 
 
Diagnosis                                                       Diagnosis                            No diagnosis 
 
 
18
FDG-PET/CT 
 
 
                                                           Abnormal                                               Normal 
 
 
 
 Biopsy         Temporal artery biopsy if >55y    
                          Bone marrow biopsy 
                                                                                                    Funduscopy and colonoscopy 
 
 
                                              Diagnosis                                          No diagnosis 
 
 
                                                                      Stable condition               Severe clinical condition   
 
 
Close follow-up                    Repeat investigations 
                                                                                                              Consider therapeutic trial 
 
*First level investigations: haemoglobin, platelet count, leukocyte count and differentiation, 
electrolytes, creatinine, protein electrophoresis, alkaline phosphatase, ALAT, LDH, creatine 
 14 
kinase, C reactive protein, blood culture (n=3), urinalysis, urine culture, tuberculin skin test, 
blood serum tests (CMV, EBV, Toxoplasmosis, HIV), chest and abdominalCT. 
**Second level investigations: Q fever, bartonella, brucella blood serum tests and otherblood 
serum tests according to the epidemiological characteristics of the patient, antinuclear 
antibodies and rheumatoid factor, microscopescreening foracid-fast bacilli on a smear, lower 
limb venous Doppler 
 
Figure 3 : TEP au  FDG dans une infection de prothèse vasculaire 
Figure 3: focal enhanced FDG uptake in a vascular endoprosthesis infection 
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